HRP20150120T1 - Materijal i metode za lijeäśenje poremeä†aja u razvoju ukljuäśujuä†i komorbidni i idiopatski autizam - Google Patents
Materijal i metode za lijeäśenje poremeä†aja u razvoju ukljuäśujuä†i komorbidni i idiopatski autizam Download PDFInfo
- Publication number
- HRP20150120T1 HRP20150120T1 HRP20150120TT HRP20150120T HRP20150120T1 HR P20150120 T1 HRP20150120 T1 HR P20150120T1 HR P20150120T T HRP20150120T T HR P20150120TT HR P20150120 T HRP20150120 T HR P20150120T HR P20150120 T1 HRP20150120 T1 HR P20150120T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- use according
- doses
- acetyl
- subject
- Prior art date
Links
- 206010003805 Autism Diseases 0.000 title claims 2
- 208000020706 Autistic disease Diseases 0.000 title claims 2
- 208000012239 Developmental disease Diseases 0.000 title 1
- MWPJTIOMWPXZFB-UHFFFAOYSA-N 1-aminopropylsulfonyl acetate Chemical compound NC(CC)S(=O)(=O)OC(C)=O MWPJTIOMWPXZFB-UHFFFAOYSA-N 0.000 claims 7
- 208000029560 autism spectrum disease Diseases 0.000 claims 6
- 210000001766 X chromosome Anatomy 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- QZTUMZPRMBJWCG-UHFFFAOYSA-L calcium;1-acetamidopropane-1-sulfonate Chemical compound [Ca+2].CCC(S([O-])(=O)=O)NC(C)=O.CCC(S([O-])(=O)=O)NC(C)=O QZTUMZPRMBJWCG-UHFFFAOYSA-L 0.000 claims 2
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000848 glutamatergic effect Effects 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 230000005062 synaptic transmission Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Pripravak koji uključuje najmanje jedan element izabran iz skupine koju čine acetil aminopropan sulfonat i neka sol acetil aminopropan sulfonata za primjenu u liječenju nekog subjekta koji ima sindrom fragilnog X kromosoma.
2. Pripravak koji uključuje najmanje jedan element izabran iz skupine koju čine acetil aminopropan sulfonat i neka sol acetil aminopropan sulfonata za primjenu u liječenju nekog subjekta koji ima neki poremećaj iz autističnog spektra.
3. Pripravak za primjenu prema zahtjevu 2, naznačen time da taj poremećaj iz autističnog spektra uključuje Aspergerov sindrom.
4. Pripravak za primjenu prema zahtjevu 2, naznačen time da taj poremećaj iz autističnog spektra uključuje idiopatski autizam.
5. Pripravak za primjenu prema zahtjevu 2, naznačen time da taj poremećaj iz autističnog spektra uključuje neki pervazivni poremećaj u razvoju koji nije inače specificiran.
6. Pripravak za primjenu prema zahtjevu 1 ili zahtjevu 2, naznačen time da spomenuti element izabran iz skupine koju čine acetil aminopropan sulfonat i neka sol acetil aminopropan sulfonata smanjuje glutamatergičnu neurotransmisiju signala.
7. Pripravak za primjenu prema zahtjevu 1 ili zahtjevu 2, naznačen time da spomenuta sol acetil aminopropan sulfonata uključuje kalcijev acetilaminopropan sulfonat prikazan Formulom I:
[image]
8. Pripravak za primjenu prema zahtjevu 7, naznačen time da je taj kalcijev acetil aminopropan sulfonat namijenjen za davanje dotičnom subjektu u dozi od najmanje jednog elementa izabranog iz dotične skupine, koja se sastoji od: jedne doze od 333 mg; doze od 666 mg; doze od 999 mg; doze od 1332 mg; doze od 1665 mg; doze od 1998 mg; doze od 2331 mg; doze od 2664 mg; i doze od 2997 mg.
9. Pripravak za primjenu prema zahtjevu 8, formuliran na način da se dotičnom subjektu dnevno daje kao jednokratna doza.
10. Pripravak za primjenu prema zahtjevu 8, formuliran na način da se dotičnom subjektu dnevno daje u više doza, na primjer tri doze dnevno.
11. Pripravak za primjenu prema zahtjevu 1 ili zahtjevu 2, naznačen time da je dotični subjekt čovjek.
12. Pripravak za primjenu prema zahtjevu 10, koji uključuje Formulu I:
[image]
za primjenu u liječenju čovjeka koji ima sindrom fragilnog X kromosoma, naznačen time da se njegovo korištenje sastoji od davanja tog pripravka dotičnom čovjeku u dozi od 333 mg takvom učestalošću da se barem jedan element izabran iz spomenute skupine daje dva puta dnevno i tri puta dnevno.
13. Pripravak za primjenu prema zahtjevu 10 koji uključuje Formulu I:
[image]
za primjenu u liječenju čovjeka koji ima neki poremećaj iz autističnog spektra, naznačen time da se njegovo korištenje sastoji od davanja tog pripravka dotičnom čovjeku u dozi od 333 mg takvom učestalošću da se barem jedan element izabran iz spomenute skupine daje dva puta dnevno i tri puta dnevno.
14. Pripravak za primjenu prema zahtjevu 2 ili zahtjevu 13, naznačen time da dotični subjekt nadalje ima sindrom fragilnog X kromosoma.
15. Pripravak za primjenu prema zahtjevu 1 ili zahtjevu 12, naznačen time da naznačen time da dotični subjekt nadalje ima neki poremećaj iz autističnog spektra.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15185809P | 2009-02-12 | 2009-02-12 | |
| PCT/US2010/024008 WO2010093859A1 (en) | 2009-02-12 | 2010-02-12 | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
| EP10705949.5A EP2395990B1 (en) | 2009-02-12 | 2010-02-12 | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150120T1 true HRP20150120T1 (hr) | 2015-05-08 |
Family
ID=42103866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150120TT HRP20150120T1 (hr) | 2009-02-12 | 2015-02-02 | Materijal i metode za lijeäśenje poremeä†aja u razvoju ukljuäśujuä†i komorbidni i idiopatski autizam |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9463172B2 (hr) |
| EP (1) | EP2395990B1 (hr) |
| JP (1) | JP5688035B2 (hr) |
| AU (1) | AU2010213683B2 (hr) |
| CA (1) | CA2781830C (hr) |
| DK (1) | DK2395990T3 (hr) |
| ES (1) | ES2530047T3 (hr) |
| HR (1) | HRP20150120T1 (hr) |
| PL (1) | PL2395990T3 (hr) |
| PT (1) | PT2395990E (hr) |
| SI (1) | SI2395990T1 (hr) |
| WO (1) | WO2010093859A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110294879A1 (en) * | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| US20130296430A1 (en) * | 2012-05-03 | 2013-11-07 | Antonio Hardan | Compositions and methods for treating autism and autism spectrum disorder |
| EP2875355B1 (en) * | 2012-07-22 | 2020-02-05 | Indiana University Research and Technology Corporation | Modulation of sapp, sapp alpha and bdnf levels in individuals diagnosed with fxs and asd |
| US10166207B2 (en) * | 2013-06-05 | 2019-01-01 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| DK3058371T3 (da) | 2013-10-14 | 2021-08-02 | Univ Indiana Res & Tech Corp | Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd |
| EP3259600A1 (en) | 2015-02-18 | 2017-12-27 | Aston University | Diagnostic assay and treatment for preeclampsia |
| IL255343B1 (en) | 2015-05-04 | 2024-06-01 | Confluence Pharmaceuticals Llc | Essay formulations of acamprosate |
| US20180221315A1 (en) * | 2015-08-04 | 2018-08-09 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and d-cycloserine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602150A (en) | 1992-10-02 | 1997-02-11 | Research Foundation For Mental Hygiene, Inc. | Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6916821B2 (en) | 2001-04-02 | 2005-07-12 | Brown University | Methods of treating disorders with Group I mGluR antagonists |
| WO2002078745A2 (en) * | 2001-04-02 | 2002-10-10 | Brown University Research Foundation | Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia |
| DE10129265A1 (de) | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
| US20040102525A1 (en) | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
| WO2006108055A1 (en) | 2005-04-05 | 2006-10-12 | Yale University | Glutamate modulating agents in the treatment of mental disorders |
| ES2610508T3 (es) | 2006-11-22 | 2017-04-27 | Clinical Research Associates, Llc | Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo |
| EP2125017A2 (en) | 2007-01-11 | 2009-12-02 | Braincells, Inc. | Modulation of neurogenesis with use of modafinil |
| US20100317715A1 (en) | 2007-12-21 | 2010-12-16 | Vollrath Benedikt | Methods for treating neuropsychiatric conditions |
-
2010
- 2010-02-12 PL PL10705949T patent/PL2395990T3/pl unknown
- 2010-02-12 SI SI201030861T patent/SI2395990T1/sl unknown
- 2010-02-12 EP EP10705949.5A patent/EP2395990B1/en active Active
- 2010-02-12 DK DK10705949.5T patent/DK2395990T3/en active
- 2010-02-12 ES ES10705949.5T patent/ES2530047T3/es active Active
- 2010-02-12 AU AU2010213683A patent/AU2010213683B2/en active Active
- 2010-02-12 WO PCT/US2010/024008 patent/WO2010093859A1/en active Application Filing
- 2010-02-12 PT PT107059495T patent/PT2395990E/pt unknown
- 2010-02-12 US US13/201,014 patent/US9463172B2/en active Active
- 2010-02-12 JP JP2011550249A patent/JP5688035B2/ja active Active
- 2010-02-12 CA CA2781830A patent/CA2781830C/en active Active
-
2015
- 2015-02-02 HR HRP20150120TT patent/HRP20150120T1/hr unknown
-
2016
- 2016-06-24 US US15/192,535 patent/US9956189B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010213683A1 (en) | 2011-09-01 |
| US9956189B2 (en) | 2018-05-01 |
| CA2781830C (en) | 2018-03-27 |
| US20120016036A1 (en) | 2012-01-19 |
| WO2010093859A1 (en) | 2010-08-19 |
| US9463172B2 (en) | 2016-10-11 |
| SI2395990T1 (sl) | 2015-04-30 |
| JP5688035B2 (ja) | 2015-03-25 |
| ES2530047T3 (es) | 2015-02-26 |
| US20160303057A1 (en) | 2016-10-20 |
| AU2010213683B2 (en) | 2016-04-21 |
| EP2395990B1 (en) | 2015-01-07 |
| PL2395990T3 (pl) | 2015-04-30 |
| EP2395990A1 (en) | 2011-12-21 |
| PT2395990E (pt) | 2015-02-09 |
| JP2012517480A (ja) | 2012-08-02 |
| DK2395990T3 (en) | 2015-02-23 |
| CA2781830A1 (en) | 2010-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150120T1 (hr) | Materijal i metode za lijeäśenje poremeä†aja u razvoju ukljuäśujuä†i komorbidni i idiopatski autizam | |
| HRP20201243T1 (hr) | N-piperidinil acetamidni derivati kao blokatori kalcijevog kanala | |
| AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
| HRP20171175T1 (hr) | Novi triciklički spojevi | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| CL2017000829A1 (es) | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. | |
| RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
| HRP20110451T1 (hr) | Upotreba izotiocijanata kao sredstva protiv mieloma | |
| BRPI0507966A (pt) | uso de meloxicam para o tratamento de doenças respiratórias em porcos | |
| HRP20150819T1 (hr) | Derivati metastina i njihova uporaba | |
| IL183360A (en) | 12-aryl prostaglandin analogs, compositions comprising them and their use in the preparation of medicaments | |
| ATE538774T1 (de) | Pharmazeutische formulierungen und verfahren zur behandlung von atemwegsinfektionen | |
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| BRPI0513455A (pt) | formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada | |
| RS54438B1 (en) | PHARMACEUTICAL DOSAGE FORM CONTAINING 6`-FLUORO- (N-METHYL-OR N, N-DIMETHYL) - 4-PHENYL-4`, 9`-DIHYDRO-3`H-SPIRO [CYCLOHEXANE-1,1`-PIRANO [3,4, B] INDOL] -4-AMINE | |
| ATE410424T1 (de) | Spirocyclische cyclohexan-derivate | |
| ME01617B (me) | Dugotrajno tretiranje hiv-infekcije s tcm278 | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| IL198180A (en) | Salt p- toluene 5-amino-3-sulfonic acid (2'-0-acetyl-3'-deoxy-ß-d-riboforanosyl) -3h-thiazole [5,4- d] pyrimidine-2-on crystalline form , A pharmaceutical product containing it, its use in the preparation of a drug and methods for its manufacture | |
| ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| AR084093A1 (es) | Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica | |
| EA201270573A1 (ru) | Гранулированный в расплаве цинакальцет | |
| RU2013157398A (ru) | Композиция | |
| BR112015019776A2 (pt) | comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos |